Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2006

View Archived Issues

AEterna Zentaris presents pipeline round-up

Orphan drug designation for Valortim in treatment of anthrax infection

Phase III efficacy trials begin for Technosphere Insulin

Priority review for TMC-114

Infinity and Novartis collaborate on Bcl-2 family inhibitors

Nereus closes second tranche of financing

Velcade studied in combination with pemetrexed for advanced NSCLC

Enrollment completed in phase I study of Chemophase for bladder cancer

Endovasc submits phase IIIa Liprostin protocol to FDA

Positive results for CX-717 in adults with ADHD

Positive Advisory Committee vote for Cubicin sNDA

Anti-rabies monoclonal antibody combination effective in vitro and in vivo

Mometasone nasal spray reduces nasal polyps

Intraperitoneal chemotherapy beneficial in patients with ovarian cancer

Safety, pharmacokinetics and comparative efficacy of BAY-59-7939 evaluated

LS-104 targets mutated Flt3 to provide enhanced anti-AML activity

Novel agents for nephritis disclosed in recent Shionogi patent

Xyrem launched for excessive daytime sleepiness in narcolepsy patients

Dasatinib NDA accepted for priority review

Recent patents cover therapeutic agents for neurological disorders

Novel antidiabetic agents disclosed in recent patents

S-236 cream may be used to promote barrier repair in atopic dermatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...